*Arcturus Therapeutics: ARCT-810 Generally Safe and Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers in Ongoing Phase 2 Study >ARCT

Dow Jones · 1d ago

Please log in to view news